Literature DB >> 6326709

Differing cardiotropic and myocarditic properties of group B type 4 coxsackievirus strains.

Y Cao, D P Schnurr, N J Schmidt.   

Abstract

A murine model system for evaluation of myocarditic and cardiotropic properties of strains of group B, type 4 coxsackievirus (CBV-4) was developed in male BALB/c mice 4 weeks of age. Differing cardiotropic and myocarditic properties could be identified among field strains within the CBV-4 serotype. These properties were consistent for the virus strains, and were independent of the infecting virus dose. Virus replication in the heart appeared to be essential for development of myocarditis, but some infected hearts with high levels of infectious virus did not show myocarditis. Two of the myocarditic strains showed different histopathology in infected hearts; with one strain (Mil) the myocarditis was characterized by a marked inflammatory reaction with occasional accompanying myofiber necrosis. With the other strain (Bol), necrosis was the predominant finding, with a much lesser degree of inflammation. These findings suggest that there may be various pathogenic or immunopathogenic mechanisms by which CBV-4 can produce myocarditis.

Entities:  

Mesh:

Year:  1984        PMID: 6326709     DOI: 10.1007/bf01310653

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  11 in total

1.  Intratypic antigenic heterogeneity of Coxsackie B viruses.

Authors:  R WIGAND; A B SABIN
Journal:  Arch Gesamte Virusforsch       Date:  1962

2.  The pathogenesis of Coxsackie group B viruses in experimental infection.

Authors:  E I GRODUMS; G DEMPSTER
Journal:  Can J Microbiol       Date:  1962-02       Impact factor: 2.419

3.  Spontaneous cardiac lesions in mice; their bearing on attempts to produce experimental carditis.

Authors:  F G GRAY
Journal:  Am J Pathol       Date:  1949-11       Impact factor: 4.307

Review 4.  Viral myocarditis. A review.

Authors:  J F Woodruff
Journal:  Am J Pathol       Date:  1980-11       Impact factor: 4.307

5.  A cardiomyopathy of BALB/c mice (superimposed infection by coxsackievirus B-3).

Authors:  F M Wilson; A M Lerner
Journal:  Proc Soc Exp Biol Med       Date:  1978-03

6.  Experimental coxsackievirus endocarditis.

Authors:  G E Burch; N P DePasquale; S C Sun; A R Hale; W J Mogabgab
Journal:  JAMA       Date:  1966-04-25       Impact factor: 56.272

7.  Variable susceptibility of mice to group B coxsackievirus infections.

Authors:  L L Minnich; C G Ray
Journal:  J Clin Microbiol       Date:  1980-01       Impact factor: 5.948

8.  Age-dependent pathogenicity of group B coxsackieviruses in Swiss-Webster mice: infectivity for myocardium and pancreas.

Authors:  R Khatib; J L Chason; B K Silberberg; A M Lerner
Journal:  J Infect Dis       Date:  1980-03       Impact factor: 5.226

9.  Coxsackievirus B4 myocarditis in mice: valvular changes in virus-infected and control animals.

Authors:  M R el-Khatib; J L Chason; K L Ho; B Silberberg; A M Lerner
Journal:  J Infect Dis       Date:  1978-04       Impact factor: 5.226

10.  Diversity within a human isolate of coxsackie B4: relationship to viral-induced diabetes.

Authors:  P C Hartig; G E Madge; S R Webb
Journal:  J Med Virol       Date:  1983       Impact factor: 2.327

View more
  3 in total

1.  Derivation and characterization of an efficiently myocarditic reovirus variant.

Authors:  B Sherry; F J Schoen; E Wenske; B N Fields
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

2.  Characterization of a murine model of myocarditis induced by a reactivated coxsackievirus B3.

Authors:  H Zhang; G E Yousef; X Ouyang; L C Archard
Journal:  Int J Exp Pathol       Date:  1994-04       Impact factor: 1.925

3.  Morphologic and phenotypic characteristics of myocarditis in two pigs infected by foot-and mouth disease virus strains of serotypes O or A.

Authors:  Carolina Stenfeldt; Juan M Pacheco; Manuel V Borca; Luis L Rodriguez; Jonathan Arzt
Journal:  Acta Vet Scand       Date:  2014-07-12       Impact factor: 1.695

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.